Drs Chan and Hunter discuss asciminib in first-line CML, OPTIC trial data on ponatinib dosing, mutational testing, and stem cell transplant strategies.
SABCS 2024 saw a variety of potentially practice-changing findings on novel antibody drug conjugates, biomarker data, and surgical interventions.
Andre Goy, MD, discusses top hematologic oncology research from the 2024 ASH Annual Meeting.
In an interview, Antoni Vilaseca Cabo, MD, discussed the clinical activity of TAR-210 in patients with non-muscle invasive bladder cancer.
“I love science, and I love medicine. And when you’re honored in this way by a society that means a lot to you both personally…
2024 Most Read Articles | Blood Advances | American Society of Hematology Top Ten Most Read Articles in 2024 Blood Advances is pleased to announce…
Carsten Niemann, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, comments on the long-term results of the Phase III GLOW study (NCT03462719), a trial evaluating first-line…
This project will evaluate the feasibility and reproducibility of novel WB-MRI for the characterization of pre-malignant lesions in NF-1 patients.
Margaret Gatti-Mays, MD MPH, The Ohio State University, Columbus, OH, discusses a Phase Ib/II trial (NCT06026657) of naxitamab, an anti-GD2 monoclonal antibody, gemcitabine, with TGFβ-imprinted,…
2024 Most Read Articles | Blood | American Society of Hematology Top Ten Most Read Articles in 2024 Blood is pleased to announce the following…
AACR Special Conference in Cancer Research: Acute Lymphoblastic Leukemia
